ALBANY, New York, April 4, 2017 - MarketResearchReports.biz has added a new report to its repository, titled, “Global Anticoagulant Market 2017-2021.” The report examines the market in-depth to understand its size and scope. It also sheds light on the current competitive dynamics in the market.
The report predicts the global anticoagulant market to clock a healthy CAGR of 7.42% from 2017 to 2021.
Anticoagulants thwart clot formations and also help prevent enlargement of existing clots in the arteries or veins. Some of the anticoagulants available in the market are heparins, including unfractionated heparin (UFH) and low molecular weight heparin (LMWH); factor Xa inhibitors; and vitamin K antagonists. They are used for indications such as angina, heart attack, deep venous thrombosis (DVT), stroke, pulmonary embolism (PE), surgery, dialysis, atrial fibrillation (AF), thrombocytopenia, and myocardial infarction.
The report finds that robust demand for novel oral anticoagulant (NOACs) has been at the forefront of driving demand in the global market for anticoagulants. NOACs target either thrombin or factor Xa to thwart and cure thrombosis. They act fast and do not require continued monitoring. They are also safer and more effective, compared to conventional therapies such as warfarin.
Other factors driving the market are the rising prevalence of coagulation disorders and growth in hip and knee surgeries. Countering the growth in the market, on the other hand, is the steep cost of NOACs and dearth of antidotes in the market for NOACs. Patent expiries paving the way for generics will also likely impede the market’s growth in the near future. Some of the noticeable trends in the market are different patient assistance programs gaining traction.
For Sample Copy, click here: http://www.marketresearchreports.biz/sample/sample/1027767
Having discussed the growth drivers, restraints, and current trends, the report goes on to segment the market based on different parameters and study each segment in details. Based on application, it classifies the market into DVT, AF, PE, etc. Depending upon ROA, the global market for anticoagulant can be further divided into oral anticoagulants and injectable anti-coagulants.
Geography-wise, the key segments analyzed in the report are the Americas, the Asia Pacific, and the Europe, Middle East, and Africa. Among them, the Americas hold a dominant position in terms of market share and will continue doing so in the next few years on account of the swift pace of introduction of NOACs.
To assess the competition prevailing in the global anticoagulant market, the report leverages Porter’s Five Forces analysis. It finds that astute players are increasingly focusing on strategic alliances to bolster their positions in the market and also increasingly looking to make inroads into the lucrative developing market’s economies. Some of the key players operating in the market that have been profiled in the report include Bristol-Myers Squibb, Bayer HealthCare, Daiichi Sankyo, Sanofi, Boehringer Ingelheim, and Johnson & Johnson.
To order report Call Toll Free: 866-997-4948 or send an email on firstname.lastname@example.org